Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Conditions

Colorectal cancerHER2 positive resectable esophagogastric adenocarcinoma

Phase 1

NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma

RecruitingCTIS2024-518841-12-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHHER2 positive resectable esophagogastric adenocarcinoma

Start: 2025-03-25Target: 39Updated: 2025-12-01

Phase 2

FUTURE platform trial – A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities

RecruitingCTIS2024-517573-24-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHColorectal cancer

Start: 2025-12-08Target: 33Updated: 2025-12-02